Cellebrite DI Ltd. $CLBT is Greenhaven Road Investment Management L.P.’s 4th Largest Position

Greenhaven Road Investment Management L.P. decreased its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 3.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,518,047 shares of the company’s stock after selling 54,046 shares during the quarter. Cellebrite DI accounts for about 8.3% of Greenhaven Road Investment Management L.P.’s investment portfolio, making the stock its 4th largest position. Greenhaven Road Investment Management L.P. owned approximately 0.63% of Cellebrite DI worth $24,289,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Clal Insurance Enterprises Holdings Ltd grew its holdings in Cellebrite DI by 17.1% during the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company’s stock valued at $62,608,000 after purchasing an additional 570,000 shares during the period. Voss Capital LP raised its stake in shares of Cellebrite DI by 18.6% in the first quarter. Voss Capital LP now owns 3,843,602 shares of the company’s stock worth $74,681,000 after buying an additional 603,602 shares during the period. Invesco Ltd. lifted its position in shares of Cellebrite DI by 6.4% during the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after buying an additional 209,473 shares in the last quarter. T. Rowe Price Investment Management Inc. bought a new position in shares of Cellebrite DI during the 1st quarter valued at approximately $60,939,000. Finally, Pertento Partners LLP increased its holdings in Cellebrite DI by 11.8% in the 2nd quarter. Pertento Partners LLP now owns 2,945,641 shares of the company’s stock worth $47,130,000 after acquiring an additional 309,988 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on CLBT shares. Bank of America lifted their price target on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday. Needham & Company LLC upped their target price on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. JPMorgan Chase & Co. raised their price target on Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Finally, Wall Street Zen lowered Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $24.00.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $18.20 on Friday. The firm has a market capitalization of $4.36 billion, a P/E ratio of 58.71, a price-to-earnings-growth ratio of 3.07 and a beta of 1.29. The company’s 50-day moving average is $17.78 and its 200 day moving average is $16.52. Cellebrite DI Ltd. has a 1-year low of $13.10 and a 1-year high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). The business had revenue of $126.03 million for the quarter, compared to analysts’ expectations of $122.98 million. Cellebrite DI had a net margin of 16.74% and a return on equity of 20.81%. Cellebrite DI’s revenue was up 17.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.14 EPS. Research analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.